ConductScience.org, home

Paper32758477

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.

Johnson DB and 7 others. Lancet Oncol, 2020. Cited by 92 papers, by iCite.

Cite this record

ConductScience Library. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Papers, record 32758477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32758477

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.
PubMed
Journal
Lancet Oncol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
92
iCite
Relative citation ratio, by iCite
3.52
iCite
Revised in PubMed
2020-08-21
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Johnson DBDouglas B
2Reynolds KLKerry L
3Sullivan RJRyan J
4Balko JMJustin M
5Patrinely JRJames R
6Cappelli LCLaura C
7Naidoo JJarushka
8Moslehi JJJavid J

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
NeoplasmsMajor topic
Humans
Medical Oncology
Patient Care
Patient Education as Topic

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K23 CA204726NCI NIH HHSUnited StatesK23CA204726PubMed and NIHNIH RePORTER
R01 CA227481NCI NIH HHSUnited StatesR01CA227481PubMed and NIHNIH RePORTER
K23 AR075872NIAMS NIH HHSUnited StatesK23AR075872PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by74

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.

PMIDTitleJournalYearIn PapersSource
42985639Long non-coding RNA prompts immune-related adverse events risk and immunotherapy response in pan-cancer.iScience2026https://conductscience.org/library/papers/42985639PubMed
42973799
Exploring real-world unmet clinical needs among patients on first-line treatment with HER2-negative advanced gastric, gastroesophageal junction or esophageal adenocarcinoma in Asia, Europe and the United States.
Front Oncol2026https://conductscience.org/library/papers/42973799PubMed
42886418Exploring uncertainties in melanoma management: a Spanish multidisciplinary Delphi consensus.Clin Transl Oncol2026https://conductscience.org/library/papers/42886418PubMed
42780081Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system.Front Immunol2026https://conductscience.org/library/papers/42780081PubMed
42759982CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.J Immunother Cancer2026https://conductscience.org/library/papers/42759982PubMed
42721039B cell-guided inflammatory cascade perpetuates ICI-mediated colitis.Cell Rep2026https://conductscience.org/library/papers/42721039PubMed
42496605Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS.Technol Cancer Res Treat2026https://conductscience.org/library/papers/42496605PubMed
41483376Immune checkpoint blockade in cancer: current insights and future horizons.Discov Oncol2026https://conductscience.org/library/papers/41483376PubMed
41357215Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Front Immunol2025https://conductscience.org/library/papers/41357215PubMed
41084760User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol.Future Oncol2025https://conductscience.org/library/papers/41084760PubMed
40949101Evolving tumor microenvironment: Driving cancer initiation and progression in cardiovascular diseases.iScience2025https://conductscience.org/library/papers/40949101PubMed
40900883Asymptomatic Troponin Elevation and Early Mortality Following Immune Checkpoint Inhibitor Therapy in Patients Without Cardiac Adverse Events.Cancer Diagn Progn2025https://conductscience.org/library/papers/40900883PubMed
40865971Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis.Int J Surg2026https://conductscience.org/library/papers/40865971PubMed
40752492Cardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering.Cell Rep Med2025https://conductscience.org/library/papers/40752492PubMed
39583866Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study.JACC Adv2024https://conductscience.org/library/papers/39583866PubMed
39578288Clinical and histopathological features of immune checkpoint inhibitor-induced lung toxicity.Virchows Arch2025https://conductscience.org/library/papers/39578288PubMed
39489880Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review.Br J Cancer2025https://conductscience.org/library/papers/39489880PubMed
39254897Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications.Curr Heart Fail Rep2024https://conductscience.org/library/papers/39254897PubMed
39062138Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis.Biomedicines2024https://conductscience.org/library/papers/39062138PubMed
38982146Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.Nat Rev Cancer2024https://conductscience.org/library/papers/38982146PubMed

See all 74 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32758477

GET https://conductscience.org/api/papers/v1/32758477/cited_by?page=2